Risk Factors of Carbapenem-resistant Enterobacteriaceae Acquisition at a Community-based Hospital |
Lee, Yeonju
(Graduate School of Converging Clinical & Public Health, Ewha Womans University)
Kang, Ji Eun (College of Pharmacy, Ewha Womans University) Ham, Jung Yeon (Department of Pharmacy, Kangbuk Samsung Medical Center) Lee, Ja Gyun (Department of Pharmacy, Kangbuk Samsung Medical Center) Rhie, Sandy Jeong (Graduate School of Converging Clinical & Public Health, Ewha Womans University) |
1 | King M, Heil E, Kuriakose S et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61(7). |
2 | Papadimitriou-Olivgeris M, Bartzavali C, Spyropoulou A et al. Molecular epidemiology and risk factors for colistin- or tigecyclineresistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period. Diagn Microbiol Infect Dis. 2018;92(3):235-40. DOI |
3 | Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943-50. |
4 | Yamamoto N, Asada R, Kawahara R, et al. Prevalence of, and risk factors for, carriage of carbapenem-resistant Enterobacteriaceae among hospitalized patients in Japan. J Hosp Infect. 2017;97(3):212-17. DOI |
5 | McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier S, Uhlemann AC. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS One. 2017; 12(10):e0186195. DOI |
6 | Ling ML, Tee YM, Tan SG, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015;4:26. DOI |
7 | Lavagnoli LS, Bassetti BR, Kaiser TDL, Kutz KM, Cerutti C Junior. Factors associated with acquisition of carbapenem-resistant Enterobacteriaceae1. Rev Lat Am Enfermagem. 2017;25: e2935. |
8 | Bassetti M, Peghin M, Pecori D. The management of multi-drugresistant enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583-94. DOI |
9 | Kang JS, Yi J, Ko MK, Lee SO, Lee JE, Kim KH. Prevalence and risk factors of carbapenem-resistant enterobacteriaceae acquisition in an emergency intensive care unit in a tertiary hospital in korea: a case-control study. J Korean Med Sci. 2019;34(18):e140. DOI |
10 | Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R. Worldwide experience with the use of doripenem against extendedspectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother. 2010;54(5):2119-24. |
11 | Queenan AM, Bush K. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev. 2007;20(3):440-58. DOI |
12 | Naas T. and Nordmann P. Analysis of a carbapenem-hydrolyzing class A beta-lactamase from Enterobacter cloacae and of its LysRtype regulatory protein. Proc Natl Acad Sci USA. 1994;91(16): 7693-97. |
13 | World Health Organization 2017. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: WHO Document Production services, 2017. |
14 | Kim YK, Song SA, Lee JN et al. Clinical factors predicting persistent carriage of Klebsiella pneumoniae carbapenemaseproducing carbapenem-resistant Enterobacteriaceae among patients with known carriage. J Hosp Infect. 2018;99(4):405-12. DOI |
15 | Papst L, Beovic B, Pulcini C et al. Antibiotic treatment of infections caused by carbapenem-resistant gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070-6. |
16 | Chabah M, Chemsi M, Zerouali K et al. Healthcare-associated infections due to carbapenemase-producingEnterobacteriaceae: Bacteriological profile and risk factors. Med Mal Infect. 2016;46(3):157-62. DOI |
17 | Salomal MC, Guimaraes T, Duailibi DF et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect. 2017;97(3):241-6. DOI |
18 | Lee HJ, Choi JK, Cho SY et al. Carbapenem-resistant enterobacteriaceae: prevalence and risk factors in a single community-based hospital in Korea. Infect Chemother. 2016;48(3):166-73. DOI |
19 | Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis. 2019;94(4):413-25. DOI |
20 | Korea Centers for Disease Control and Prevention 2018. Guidelines for healthcare assosicated infectious disease (VRSA, CRE). Government publications registration number 11-1352159-00832-10. |